Stock of The Day: Will AcelRx Pharmaceuticals Inc Short Squeeze Soon?

Stock of The Day: Will AcelRx Pharmaceuticals Inc Short Squeeze Soon?

The stock of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is a huge mover today! About 106,750 shares traded hands. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has risen 7.32% since March 8, 2016 and is uptrending. It has underperformed by 1.99% the S&P500.
The move comes after 5 months negative chart setup for the $167.99M company. It was reported on Oct, 11 by Barchart.com. We have $3.18 PT which if reached, will make NASDAQ:ACRX worth $20.16M less.

Analysts await AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to report earnings on November, 3. They expect $-0.23 EPS, down 309.09% or $0.34 from last year’s $0.11 per share. After $-0.24 actual EPS reported by AcelRx Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -4.17% EPS growth.

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Ratings Coverage

Out of 5 analysts covering AcelRx Pharmaceuticals (NASDAQ:ACRX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. AcelRx Pharmaceuticals has been the topic of 11 analyst reports since August 4, 2015 according to StockzIntelligence Inc. TH Capital maintained the stock with “Buy” rating in Thursday, September 15 report. The stock of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) earned “Buy” rating by Seaport Global on Friday, May 6. The stock of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has “Hold” rating given on Tuesday, August 4 by Cowen & Co. Roth Capital maintained AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) on Monday, October 5 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, May 3 report. The stock of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has “Buy” rating given on Friday, October 30 by Jefferies. The firm earned “Buy” rating on Monday, October 5 by TH Capital. H.C. Wainwright initiated the stock with “Buy” rating in Wednesday, September 2 report.

According to Zacks Investment Research, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California.”

Insitutional Activity: The institutional sentiment increased to 0.94 in 2016 Q2. Its up 0.30, from 0.64 in 2016Q1. The ratio increased, as 17 funds sold all AcelRx Pharmaceuticals Inc shares owned while 14 reduced positions. 15 funds bought stakes while 14 increased positions. They now own 16.10 million shares or 4.22% more from 15.45 million shares in 2016Q1.
Wells Fargo & Company Mn last reported 0% of its portfolio in the stock. Guggenheim Cap Ltd Liability Corporation holds 10,531 shares or 0% of its portfolio. California State Teachers Retirement has 0% invested in the company for 74,215 shares. The New York-based Teachers Advisors has invested 0% in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Oxford Asset Management accumulated 153,769 shares or 0.02% of the stock. Millennium Mgmt Ltd Llc has 46,100 shares for 0% of their US portfolio. Pdts Prns Limited Liability Company last reported 55,399 shares in the company. Blackrock Investment Management Ltd Co has invested 0% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). The Pennsylvania-based Nationwide Fund Advisors has invested 0% in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Grt Capital Prtn Limited Com holds 0.09% or 127,846 shares in its portfolio. Nippon Life Insurance Company has invested 0.06% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). The New York-based Fincl Bank Of New York Mellon has invested 0% in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Manufacturers Life Ins The accumulated 1,791 shares or 0% of the stock. Moreover, Service Automobile Association has 0% invested in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) for 271,770 shares. Blackrock Fund Advsr accumulated 0% or 921,567 shares.

Insider Transactions: Since May 10, 2016, the stock had 2 insider buys, and 2 sales for $2.22 million net activity. $1.45M worth of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) was sold by PERCEPTIVE ADVISORS LLC on Thursday, September 15. Shares for $47,250 were bought by EDWARDS MARK G on Tuesday, May 10. Rosen Howard B bought $33,272 worth of stock.

More notable recent AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) news were published by: Prnewswire.com which released: “AcelRx Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare …” on September 22, 2016, also Prnewswire.com with their article: “AcelRx Pharmaceuticals to Present Initial Results of Phase 3 Study of ARX‑04 …” published on August 01, 2016, Prnewswire.com published: “AcelRx Initiates Phase 3 Study of Zalviso® in Patients with Moderate-to-Severe …” on September 27, 2016. More interesting news about AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) were released by: Prnewswire.com and their article: “AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September” published on August 31, 2016 as well as Prnewswire.com‘s news article titled: “AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and …” with publication date: March 29, 2016.

ACRX Company Profile

AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a specialty pharmaceutical firm focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Firm operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. The Company’s lead product candidates include ARX-04 and Zalviso, which utilizes sublingual sufentanil, delivered through a non-invasive route of administration. The Company’s product candidate pipeline also includes ARX-03, which is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment